AgeX Therapeutics, Inc.
AMEX:AGE
0.4302 (USD) • At close November 17, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 0.142 | 0.034 | 0.144 | 1.868 | 1.728 | 1.396 | 1.404 |
| Cost of Revenue
| 0.171 | 0.013 | 0.019 | 0.158 | 0.244 | 0.364 | 0.168 |
| Gross Profit
| -0.029 | 0.021 | 0.125 | 1.71 | 1.484 | 1.032 | 1.236 |
| Gross Profit Ratio
| -0.204 | 0.618 | 0.868 | 0.915 | 0.859 | 0.739 | 0.88 |
| Reseach & Development Expenses
| 0.603 | 1.025 | 1.456 | 4.978 | 5.904 | 6.63 | 5.784 |
| General & Administrative Expenses
| 9.328 | 5.971 | 6.708 | 7.403 | 8.139 | 5.647 | 3.869 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 9.328 | 5.971 | 6.708 | 7.403 | 8.139 | 5.647 | 3.869 |
| Other Expenses
| 0.011 | 0.013 | 0.448 | 0.044 | 0.294 | 0.183 | 0.038 |
| Operating Expenses
| 9.931 | 6.996 | 8.164 | 12.381 | 14.043 | 12.277 | 9.653 |
| Operating Income
| -9.96 | -6.975 | -8.039 | -10.671 | -12.559 | -11.245 | -6.663 |
| Operating Income Ratio
| -70.141 | -205.147 | -55.826 | -5.713 | -7.268 | -8.055 | -4.746 |
| Total Other Income Expenses Net
| -4.851 | -3.547 | -0.543 | -0.455 | 0.323 | 3.398 | 1.792 |
| Income Before Tax
| -14.811 | -10.522 | -8.582 | -11.126 | -12.236 | -7.731 | -6.637 |
| Income Before Tax Ratio
| -104.303 | -309.471 | -59.597 | -5.956 | -7.081 | -5.538 | -4.727 |
| Income Tax Expense
| -0.008 | 0.152 | 1.638 | -0.15 | 0.148 | 3.514 | -1.799 |
| Net Income
| -14.803 | -10.674 | -10.22 | -10.976 | -12.384 | -7.502 | -6.58 |
| Net Income Ratio
| -104.246 | -313.941 | -70.972 | -5.876 | -7.167 | -5.374 | -4.687 |
| EPS
| -13.72 | -9.89 | -9.49 | -10.25 | -11.69 | -7.56 | -6.46 |
| EPS Diluted
| -13.72 | -9.89 | -9.49 | -10.25 | -11.69 | -7.56 | -6.46 |
| EBITDA
| -9.829 | -6.83 | -7.46 | -8.989 | -11.608 | -10.71 | -9.489 |
| EBITDA Ratio
| -69.218 | -200.882 | -51.806 | -4.812 | -6.718 | -7.672 | -6.759 |